Skip to main content


Latest articles

18-04-2019 | Rheumatology | News | Article

Statins may have some benefits in patients with RA

Findings from the TRACE RA trial suggest that atorvastatin has a favorable safety profile and may reduce low-density lipoprotein cholesterol levels in patients with rheumatoid arthritis.

17-04-2019 | Rheumatology | News | Article

RA flare rates unaffected by tapering strategy

Rheumatoid arthritis flare rates are similar regardless of which drug type is tapered first after achievement of disease control during conventional synthetic DMARD and tumor necrosis factor inhibitor combination therapy, research shows.

16-04-2019 | Rheumatology | News | Article

Inflammatory arthritis may impact sexual function

Findings from a systematic review suggest that sexual dysfunction is common among both men and women with inflammatory arthritis, highlighting the importance of including sexual health in the routine management of rheumatic disease.

15-04-2019 | Rheumatology | News | Article

Calprotectin levels separate septic arthritis from other inflammatory arthritides

Levels of calprotectin in the synovial fluid can be used to discriminate patients with septic arthritis from those with pseudogout and rheumatoid arthritis, shows a report published in Rheumatology.

12-04-2019 | Rheumatology | News | Article

Infliximab withdrawal not recommended for AS patients in remission

The decision to discontinue infliximab in ankylosing spondylitis patients who have achieved sustained remission “should be taken with considerable caution,” say Spanish researchers who found that over half relapsed after the tumor necrosis factor inhibitor was withdrawn.

11-04-2019 | Rheumatology | News | Article

‘Poor’ reporting of concomitant treatment in rheumatology trials

The use of concomitant medications that may influence outcomes is “poorly reported” in rheumatology trials, say researchers.

11-04-2019 | Rheumatology | News | Article

FDA approves romosozumab for fracture prevention in osteoporosis

Click through for more information on this announcement

10-04-2019 | Rheumatology | News | Article

ORAL Sequel demonstrates consistent long-term safety, efficacy profiles of tofacitinib

The Janus kinase inhibitor tofacitinib has demonstrated a consistent safety profile and sustained efficacy in rheumatoid arthritis patients over a maximum follow-up of 9.5 years, report the ORAL Sequel investigators.

09-04-2019 | Rheumatology | News | Article

Updated EULAR guidelines for lupus management issued

EULAR has published up-to-date recommendations for the management of systemic lupus erythematosus based on emerging evidence and expert opinion.

08-04-2019 | Rheumatology | News | Article

Biomarker panel may help differentiate PsA from osteoarthritis

A panel of four soluble biomarkers comprising markers of cartilage metabolism, metabolic syndrome, and inflammation could distinguish psoriatic arthritis from osteoarthritis, researchers report.

05-04-2019 | Rheumatology | News | Article

Beneficial effects of NSAIDs peak early in knee osteoarthritis

A meta-analysis of 72 randomized controlled trials including 26,424 participants with knee osteoarthritis suggests that the beneficial pain-relief effects of oral NSAIDs peak at 2 weeks, while minor adverse events begin to appear at 4 weeks.

04-04-2019 | Rheumatology | News | Article

OA, RA have similar disease burden at the time of diagnosis

Osteoarthritis is associated with a similar disease burden to rheumatoid arthritis at the time of first presentation, despite traditionally being perceived as a milder condition, researchers report.

03-04-2019 | Rheumatology | News | Article

Abatacept may not provoke respiratory events in RA patients with COPD

Individuals with rheumatoid arthritis (RA) and chronic obstructive pulmonary disease who are treated with abatacept do not have an elevated risk for adverse respiratory events relative to those given other biologics, real-world study results suggest.

02-04-2019 | Rheumatology | News | Article

Cardiovascular risk associated with conventional, biologic DMARDs characterized

Tocilizumab is associated with a lower risk for major adverse cardiovascular events than tumor necrosis factor inhibitors among patients with rheumatoid arthritis, whereas the use of conventional DMARDs may be linked to an elevated risk, researchers report.

01-04-2019 | Rheumatology | News | Article

Risk factors for dyspnea identified in RA patients

Older age, female sex, and poor functional status are significant predictors of dyspnea on exertion among patients with rheumatoid arthritis, researchers report.

29-03-2019 | Rheumatology | News | Article

FDA approves certolizumab pegol for nonradiographic axSpA

Click through for more detail on this approval

29-03-2019 | Rheumatology | News | Article

Benefits of sarilumab confirmed in Japanese RA patients

Adding sarilumab to methotrexate significantly improves the signs and symptoms of rheumatoid arthritis relative to placebo in Japanese patients with an inadequate response to methotrexate monotherapy, study findings indicate.

28-03-2019 | Rheumatology | News | Article

Support for stroke prevention strategies in SSc patients

Individuals with systemic sclerosis have an elevated risk for ischemic stroke after adjustment for traditional cardiovascular risk factors, study findings suggest.

27-03-2019 | Rheumatology | News | Article

Biologics may influence durability of yellow fever vaccine response in RA patients

Treatment with biologics in combination with conventional DMARDs is associated with a reduction in the duration of protective immunity induced by the 17DD yellow fever vaccine among patients with rheumatoid arthritis, research suggests.

26-03-2019 | Rheumatology | News | Article

EMA warns of increased risk for pulmonary embolism and death with higher dose of tofacitinib

Click through for further details on this safety alert

image credits